Key Updates in Mantle Cell Lymphoma from ASH 2023

Listen to Mats Jerkeman present the latest updates on mantle cell lymphoma from the ASH meeting. He highlights the late-breaking abstract SYMPATICO trial, a randomized phase III study for relapsed/refractory mantle cell lymphoma, comparing ibrutinib plus placebo to ibrutinib and venetoclax. A treatment that can be a new standard for at least younger patients with relapsed mantle cell lymphoma. Another notable study compared Rituximab and Obinutuzumab in untreated patients, showing higher MRD negativity with Obinutuzumab. The data emphasizes that Obinutuzumab is probably the best CD20 antibody for mantle cell lymphoma. Finally, he highlights the data on the SHINE trial for elderly patients, suggesting R-Bendamustine followed by a BTK inhibitor as a viable treatment sequence.